Novartis gene therapy helps children with rare muscle disorder in study
Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle ...
Novartis Says New Drug Helps Children With Rare Spinal Condition
Novartis AG said a new experimental medicine improved motor function in children with a form of spinal muscular atrophy, the ...
FiercePharma4d
After delay with FDA, Novartis touts pivotal trial win for intrathecal Zolgensma in older SMA patients
More than three years after Novartis’ plan for a speedy approval for intrathecal Zolgensma was thwarted by an FDA requirement ...
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules
A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks ...
Zacks.com on MSN5d
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary ...
JD Supra1h
Investigations Newsletter: Second Circuit Partially Affirms Novartis’ Motion to Dismiss AKS Claims
Second Circuit Partially Affirms Novartis’ Motion to Dismiss AKS Claims - Last week, the Second Circuit Court of Appeals affirmed ...
Pharmaceutical Technology23h
ITU-512 by Novartis for Sickle Cell Disease: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
Novartis has reported positive topline outcomes from the Phase III STEER trial of an investigational gene therapy, ...
Pharmaceutical Technology23h
Iptacopan hydrochloride by Novartis for Proteinuria: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
pharmaphorum6d
New data could widen use of Novartis' SMA therapy Zolgensma
Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...
Novartis reports positive results for intrathecal Zolgensma
Novartis (NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma met its primary endpoint in ...
SA Asks: Which biotechs are most likely to be acquired near-term?
Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.